Prevalence of HBsAg among Moroccan HIV-1 infected patients and APOBEC3G variant frequencies in HIV-1/HBV co-infection

被引:0
|
作者
Belbacha, Imane [1 ,2 ]
Bensghir, Rajae [3 ]
Marhoum, Kamal Filali [3 ]
Laboudi, Majda [4 ]
Hajoutt, Khadija [5 ]
Elharti, Elmir [1 ]
Sadki, Khalid [2 ]
Oumzil, Hicham [1 ,6 ]
机构
[1] Natl Inst Hyg, Dept Virol, Natl Reference Lab HIV, Rabat, Morocco
[2] Mohamed V Univ, Fac Med Dent, Res Lab Oral Biol & Biotechnol, Rabat, Morocco
[3] Univ Hosp IBN ROCHD, Infect Dis Serv, Casablanca, Morocco
[4] Natl Inst Hyg, Dept Parasitol, Rabat, Morocco
[5] Natl Ctr Blood Transfus, Immuno Hematol Unit, Rabat, Morocco
[6] Mohamed V Univ, Fac Med & Pharm, Microbiol RPU, Rabat, Morocco
来源
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES | 2024年 / 18卷 / 05期
关键词
HIV-1/HBV co-infection; HBsAg; APOBEC3G; polymorphism; Morocco; HEPATITIS-B-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; C VIRUS; HIV; INFECTION; SEROPREVALENCE; ASSOCIATION; ANTIGEN; AGE;
D O I
10.3855/jidc.18781
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Human immunodeficiency virus (HIV) / hepatitis B virus (HBV) causes higher rates of liver disease compared to infection with just one virus. Co-infection can accelerate the progression to liver fibrosis or hepatocellular carcinoma and disturb the treatment response. APOBEC3G is a host defense factor which interferes with HIV-1 and HBV. We aimed to determine the prevalence of hepatitis B surface antigen (HBsAg) among HIV-infected patients and seronegative controls, and screen the HIV/HBV population for APOBEC3G variants rs8177832, rs35228531 and rs2294367, previously associated with HIV-1 infection susceptibility in Morocco. Methodology: A case control study was conducted on 404 individuals (204 HIV-infected and 200 eligible blood donors) from April to November 2021. HBsAg was measured on the Roche Cobas e411 automatic analyzer (Roche Diagnostics, Basel, Switzerland) and APOBEC3G polymorphisms were identified using the TaqMan genotyping allelic discrimination method. Fisher Exact test, odds ratio (OR) with 95% confidence interval (CI), and haplotype frequencies were calculated. Results: Of the 204 HIV-1 seropositive patients and 200 controls, 4.9% (95%CI: 2.38-8.83) and 2.50% (95% CI: 0.82-5.74) were HBsAgpositive respectively. There was a significant association between increasing age (> 40 years) and HBV infection among controls (p = 0.04). The distribution of genotypes and alleles frequencies of APOBEC3G variants was heterogenous and five different haplotypes with frequencies >= 5% were obtained, of which ACC (rs8177832, rs35228531, rs2294367) was the most prevalent. Conclusions: HBV co-infection is common among HIV-1 infected individuals in Morocco. Efforts should be made to prevent, treat and control HBV transmission in this population.
引用
收藏
页码:779 / 786
页数:8
相关论文
共 50 条
  • [31] Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G
    Cen, Shan
    Peng, Zong-Gen
    Li, Xiao-Yu
    Li, Zhuo-Rong
    Ma, Jing
    Wang, Yue-Ming
    Fan, Bo
    You, Xue-Fu
    Wang, Yu-Ping
    Liu, Fei
    Shao, Rong-Guang
    Zhao, Li-Xun
    Yu, Liyan
    Jiang, Jian-Dong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (22) : 16546 - 16552
  • [32] High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China
    Jia, Hui-Hua
    Li, Kai-Wen
    Chen, Qin-Yan
    Wang, Xue-Yan
    Harrison, Tim J.
    Liang, Shu-Jia
    Yang, Qing-Li
    Wang, Chao
    Hu, Li-Ping
    Ren, Chuang-Chuang
    Fang, Zhong-Liao
    INTERVIROLOGY, 2018, 61 (03) : 123 - 132
  • [33] Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G
    Sakuma, R.
    Noser, J. A.
    Ohmine, S.
    Ikeda, Y.
    GENE THERAPY, 2007, 14 (02) : 185 - 189
  • [34] Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G
    Kouno, Takahide
    Shibata, Satoshi
    Shigematsu, Megumi
    Hyun, Jaekyung
    Kim, Tae Gyun
    Matsuo, Hiroshi
    Wolf, Matthias
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [35] Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein
    Pan, Ting
    He, Xin
    Chen, Bing
    Chen, Hui
    Geng, Guannan
    Luo, Haihua
    Zhang, Hui
    Bai, Chuan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 95 : 500 - 513
  • [36] Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association
    Fukuda, Hirofumi
    Li, Songling
    Sardo, Luca
    Smith, Jessica L.
    Yamashita, Kazuo
    Sarca, Anamaria D.
    Shirakawa, Kotaro
    Standley, Daron M.
    Takaori-Kondo, Akifumi
    Izumi, Taisuke
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [37] Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G
    Delviks-Frankenberry, Krista A.
    Ackerman, Daniel
    Timberlake, Nina D.
    Hamscher, Maria
    Nikolaitchik, Olga A.
    Hu, Wei-Shau
    Torbett, Bruce E.
    Pathak, Vinay K.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 18 : 1023 - 1038
  • [38] Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G
    R Sakuma
    J A Noser
    S Ohmine
    Y Ikeda
    Gene Therapy, 2007, 14 : 185 - 189
  • [39] Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA
    Maiti, Atanu
    Myint, Wazo
    Kanai, Tapan
    Delviks-Frankenberry, Krista
    Rodriguez, Christina Sierra
    Pathak, Vinay K.
    Schiffer, Celia A.
    Matsuo, Hiroshi
    NATURE COMMUNICATIONS, 2018, 9
  • [40] HIV-1 and GBV-C co-infection in Venezuela
    Karely Rodriguez, Anny
    Jose Garzaro, Domingo
    Luisa Loureiro, Carmen
    Gutierrez, Cristina R.
    Ameli, Gladys
    Celeste Jaspe, Rossana
    Porto, Leticia
    Monsalve, Francisca
    Pozada, Angela
    Vasquez, Luzmary
    Quinones-Mateu, Miguel E.
    Helene Pujol, Flor
    Rafael Rangel, Hector
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2014, 8 (07): : 863 - 868